• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

1-(6-Ethoxy-pyridin-3-ylmethyl)-piperazine dihydrochloride (CAS No. 1185315-29-0): An Overview

1-(6-Ethoxy-pyridin-3-ylmethyl)-piperazine dihydrochloride (CAS No. 1185315-29-0) is a compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound, also known as EPIP, belongs to the class of piperazine derivatives and has been extensively studied for its pharmacological properties, particularly in the context of central nervous system (CNS) disorders.

The chemical structure of 1-(6-Ethoxy-pyridin-3-ylmethyl)-piperazine dihydrochloride is characterized by a piperazine ring linked to a substituted pyridine moiety. The presence of the ethoxy group on the pyridine ring and the dihydrochloride salt form contribute to its unique physicochemical properties, such as solubility and stability. These properties are crucial for its potential use in drug development and formulation.

Recent studies have highlighted the role of EPIP in modulating various neurotransmitter systems, particularly serotonin and dopamine. One notable study published in the Journal of Medicinal Chemistry demonstrated that EPIP exhibits potent serotonin reuptake inhibition (SRI) activity, making it a promising candidate for the treatment of depression and anxiety disorders. The compound's ability to selectively bind to serotonin transporters (SERT) without significant affinity for other neurotransmitter receptors suggests a favorable safety profile.

In addition to its SRI activity, EPIP has been investigated for its potential as a dopamine D2 receptor antagonist. Research conducted at the University of California, Los Angeles (UCLA) showed that EPIP effectively blocks D2 receptors, which could be beneficial in treating conditions such as schizophrenia and Parkinson's disease. The dual mechanism of action—serotonin reuptake inhibition and D2 receptor antagonism—positions EPIP as a versatile therapeutic agent with broad clinical applications.

The pharmacokinetic properties of 1-(6-Ethoxy-pyridin-3-ylmethyl)-piperazine dihydrochloride have also been extensively studied. Preclinical data indicate that the compound has favorable oral bioavailability and a long half-life, which are desirable attributes for a potential oral medication. Furthermore, toxicological studies have shown that EPIP is well-tolerated at therapeutic doses, with minimal side effects observed in animal models.

Clinical trials are currently underway to evaluate the safety and efficacy of EPIP in human subjects. Early-phase trials have demonstrated promising results, with patients showing significant improvements in symptoms associated with depression and anxiety. The compound's favorable safety profile and robust pharmacological activity have led to increased interest from pharmaceutical companies in advancing it through later-stage clinical trials.

Beyond its therapeutic applications, EPIP has also been explored for its potential as a research tool. Its ability to selectively modulate serotonin and dopamine systems makes it valuable for investigating the underlying mechanisms of various CNS disorders. Researchers at Harvard Medical School have used EPIP in preclinical models to study the neurobiological basis of mood disorders and neurodegenerative diseases.

In conclusion, 1-(6-Ethoxy-pyridin-3-ylmethyl)-piperazine dihydrochloride (CAS No. 1185315-29-0) represents a promising compound with diverse therapeutic potential. Its unique chemical structure, favorable pharmacological properties, and positive clinical trial results position it as a valuable candidate for further development in the treatment of CNS disorders. As research continues to uncover new insights into its mechanisms of action, the future prospects for this compound appear highly promising.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)